Clinical Trials Logo

Filter by:
NCT ID: NCT00617175 Completed - Heart Disease Clinical Trials

Avoid DeliVering TherApies for Non-sustained Arrhythmias in ICD PatiEnts III

ADVANCEIII
Start date: March 2008
Phase: Phase 4
Study type: Interventional

To demonstrate a reduction in the number of ventricular therapies (ATP and Shocks) delivered for treating spontaneous arrhythmia episodes with a fast cycle length (CL≤ 320ms) as a consequence of self-termination and better arrhythmia discrimination due to a greater number of R-R intervals necessary to detect ventricular events.

NCT ID: NCT00616629 Completed - Atrial Flutter Clinical Trials

Cardiac Electrophysiological Study

Start date: January 2008
Phase: Phase 2
Study type: Interventional

The purpose of the study is to measure the effects of AZD1305 on cardiac electrophysiological properties and intracardiac pressures

NCT ID: NCT00615368 Completed - Type 1 Diabetes Clinical Trials

Treatment With Erythropoietin and Cognition During Hypoglycaemia

Start date: May 2008
Phase: N/A
Study type: Interventional

The purpose of the trial is to determine if erythropoietin (EPO) can enhance cognitive function during hypoglycaemia in patients with type 1 diabetes. Patients with type 1 diabetes will receive one injection of EPO. Hypoglycaemia will be induced 6 days after. Before (1 hour), during and after (1 hour) hypoglycaemia, the cognitive function will be measured.

NCT ID: NCT00614900 Completed - COPD Clinical Trials

Prevalence of Pulmonary Hypertension in COPD Patients

Start date: March 2008
Phase: N/A
Study type: Observational

The prevalence of an increased pulmonary blood pressure amongst patients with chronic obstructive pulmonary disease (COPD)is unclear. So is the impact of abnormal pulmonary blood pressure on symptoms. The aim of this study is to determine the prevalence of an increased pulmonary blood pressure in 200 patients with COPD. Furthermore we will investigate if lung function test results and blood tests can predict an increased pulmonary blood pressure, and explore whether COPD patients with a high pulmonary blood pressure have more symptoms that their co-patients.

NCT ID: NCT00614380 Completed - Hypertension Clinical Trials

Open Label Study Telmisartan and Amlodipine in Hypertension

Start date: January 2008
Phase: Phase 3
Study type: Interventional

The primary objective of this trial is to assess the efficacy and safety of the fixed dose combinations telmisartan 40 mg / amlodipine 5 mg (T40/A5) or telmisartan 80 mg / amlodipine 5 mg (T80/A5) during long-term open-label treatment.

NCT ID: NCT00614146 Completed - Liver Failure Clinical Trials

Recompensation of Exacerbated Liver Insufficiency With Hyperbilirubinemia and/or Encephalopathy and/or Renal Failure

RELIEF
Start date: April 2003
Phase: N/A
Study type: Interventional

The objective of this trial is to evaluate the impact of elimination of albumin bound substances during albumin dialysis (MARS®) on mortality and the clinical time course in patients with a recent severe clinical deterioration of chronic liver disease caused by a precipitating (trigger) event within 4 weeks manifested by jaundice, encephalopathy and/or renal failure.

NCT ID: NCT00613912 Completed - Clinical trials for Depressive Disorder, Major

Advanced MRI in Major Depression

Start date: March 2008
Phase: N/A
Study type: Observational

Depression is the most common psychiatric disorder. - 3-5% of a given population has major depression. - Less than 50% of the depressed in Denmark are diagnosed with major depression. - 25-50% of the depressed have a relative with major depression-underlying brain pathology? The purpose of this study is to use MRI to evaluate cerebral morphology and function in ambulant patients with major depression

NCT ID: NCT00613288 Completed - Hypogonadism Clinical Trials

Testosterone and Lipolysis, Insulin Sensitivity and Protein Metabolism

Start date: September 2007
Phase: N/A
Study type: Interventional

Testosterone(T) has known effects on many organ systems, although many of its metabolic actions are unrevealed. T is an anabolic hormone stimulating protein synthesis but this effect has barely been investigated in controlled studies. It also has lipolytic actions influencing body composition, but little is known of its regional impact on fat tissue. T affects insulin sensitivity. There is an increased incidence of hypogonadism in type 2 diabetes, and among patients with hypogonadism there is an increased incidence of type 2 diabetes. The actions of testosterone on glucose metabolism are unknown. The purpose of this study is therefore to: Investigate the lipolytic effect of testosterone on muscle and fat tissue. To gain insight in the intracellular mechanisms of testosterone on lipolysis and investigate possible regional differences in lipolysis and changes in body composition. Finally to investigate the effect of short term experimental hypogonadism and acute testosterone substitution on cytokines, insulin sensitivity and protein metabolism. The trial is a randomised double blinded cross-over study of 4 x 2 days with an interval of 1 month in between. 12 healthy young men will receive GnRH treatment over a 3 month period and examined on 4 occasions with various degrees of T substitution and placebo . The examinations take place at the Research Lab within the Medical Department M. The investigations are deemed relevant to the understanding of the interrelationship between male hypogonadism and type 2 diabetes. The hypothesis is that T has beneficial effects on carbohydrate, fat and protein metabolism. The generated knowledge would therefore hopefully improve prophylaxis, screening and early treatment of both group of patients.

NCT ID: NCT00612950 Completed - Type 2 Diabetes Clinical Trials

Beta-Cell Function After Near-Normalisation of Blood Glucose

Start date: October 2006
Phase: N/A
Study type: Interventional

The incretin effect is attenuated in patients with type 2 diabetes mellitus partly due to impaired potentiation of beta-cell responsiveness to glucose by glucose dependent insulinotropic polypeptide and glucagon-like peptide-1 respectively. The aim of the present study was to investigate whether 4 weeks of near-normalization of blood glucose could improve the insulin responses to GIP and GLP-1 in patients with type 2 diabetes.

NCT ID: NCT00612664 Completed - Melanoma Clinical Trials

Phase II, 2nd Line Melanoma - RAND Monotherapy

Start date: March 2008
Phase: Phase 2
Study type: Interventional

The main purpose of this study is to estimate the proportion of patients with a type of skin cancer called melanoma who are progression free, (that is, the cancer has not gotten substantially worse), when treated with Anti-CD137 (4-1BB) (BMS-663513) at 0.1 mg/kg, 1 mg/kg or 5 mg/kg every 3 weeks or 1 mg/kg every 6 weeks